INCY vs REPL · P/E 14, rev $4.24B vs $825.7M cap
Incyte Corporation (INCY) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported INCY revenue for 2024-12-31 was $4.24B. Net income was $32.6M. Revenue was up 14.8% from 2023-12-31 to 2024-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
REPL does not have a complete income-statement cache yet.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. REPL currently screens at market cap $825.7M.
Not investment advice. Open the INCY and REPL stock pages for the full models.
Not investment advice.